When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...
Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. | For nearly a decade, Eli Lilly has been ...
On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors ...
In the span of eight months, Big Pharma companies took over four of the hottest radiopharmaceutical players in the industry.
In a phase 3 trial, Tenpoint Therapeutics’ eye drop—a combination of carbachol and brimonidine—improved vision for patients ...
FDA's Patrizia Cavazzoni to retire as CDER chief in 2nd senior official's departure in span of weeks
The FDA’s influential director of the Center for Drug Evaluation and Research, Patrizia Cavazzoni, M.D., will soon retire ...
A review of the FDA’s drug approvals of 2024 shows that small companies loomed large—both in the sheer number of nods g | ...
A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...
The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...
Matt McNally is rejoining Publicis. The ad exec has taken the global CEO post at Publicis Health, returning to a company ...
In recent years, the FDA has amped up its supervision of accelerated approvals, including by requiring that confirmatory ...
Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback